As of Jun 29
| -1.15 / -2.34%|
The 16 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 50.31, with a high estimate of 60.24 and a low estimate of 39.09. The median estimate represents a +4.54% increase from the last price of 48.13.
The current consensus among 16 polled investment analysts is to Buy stock in Novozymes A/S. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.